In the recent TROPION-PanTumor01 phase I trial, datopotamab deruxtecan, an ADC similar to trastuzumab deruxtecan, showed promising activity and low toxicity in heavily pretreated ER+/HER2− breast cancer subjects, most of them treated with a CDK4/6i [149]. This evidence concerns the gene CDK4 and breast carcinoma.